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Abstract: Worldwide dissemination of pathogens resistant to almost all available antibiotics represent
a real problem preventing efficient treatment of infectious diseases. Among antimicrobial used in
therapy, β-lactam antibiotics represent 40% thus playing a crucial role in the management of infections
treatment. We report a small series of phenylboronic acids derivatives (BAs) active against class A
carbapenemases KPC-2 and GES-5, and class C cephalosporinases AmpC. The inhibitory profile of
our BAs against class A and C was investigated by means of molecular docking, enzyme kinetics and
X-ray crystallography. We were interested in the mechanism of recognition among class A and class C
to direct the design of broad serine β-Lactamases (SBLs) inhibitors. Molecular modeling calculations
vs GES-5 and crystallographic studies vs AmpC reasoned, respectively, the ortho derivative 2 and the
meta derivative 3 binding affinity. The ability of our BAs to protect β-lactams from BLs hydrolysis was
determined in biological assays conducted against clinical strains: Fractional inhibitory concentration
index (FICI) tests confirmed their ability to be synergic with β-lactams thus restoring susceptibility to
meropenem. Considering the obtained results and the lack of cytotoxicity, our derivatives represent
validated probe for the design of SBLs inhibitors.
Keywords: Serine β-lactamases; carbapenemases; KPC-2 Klebsiella pneumoniae; GES-5 Guyana
extended-spectrum-lactamase; boronic acid; enzyme inhibitors; X-ray crystallography; synergism
1. Introduction
The emergence and worldwide spread of multidrug-resistant (MDR) Enterobacteriaceae represents
a serious public health problem [1]. Enterobacteriaceae are common pathogens responsible for
community—and hospital—acquired infections. Notably, MDR Enterobacteriaceae can produce
β-lactamases (BLs), extended-spectrum BLs (ESBLs) and BLs carbapenemases. They inactivate
the last generation of β-lactam antibiotics and the last resort carbapenems, menacing the treatment
of highly resistant infections [2–5]. Therefore, antimicrobial resistance in these bacteria causes high
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impact on the success of treatments and reduces critically the armamentarium of antimicrobials that
are still efficacious.
According to their amino acid sequences, β-lactamases are classified into class A, C, and D
enzymes, which utilize serine for β-lactam hydrolysis (SBLs), and class B metalloenzymes (MBLs),
which require divalent zinc ions for substrate hydrolysis [6].
In the panel of SBLs selected for our studies, we included the plasmid-mediated carbapenemases
KPC-2 and GES-5 for class A [7–9] and the chromosomally encoded AmpC for class C [10]. Klebsiella
pneumoniae carbapenemase (KPC)-producing organisms are resistant to nearly all available β-lactams
antibiotics (including cefotaxime) but also to other antimicrobial classes such as fluoroquinolones
and aminoglycosides [11]. GES-type β-lactamases, belonging to class A carbapenemases, have been
increasingly reported among Gram-negative pathogens, including P. aeruginosa, Enterobacter cloacae,
Klebsiella pneumoniae, and Acinetobacter baumannii. At present, 37 GES-variants have been detected
worldwide [12]. AmpC β-lactamases are clinically relevant cephalosporinases. They mediate resistance
to cephalothin, cefazolin, cefoxitin, most penicillins, and to β-lactamase inhibitor (BLI)-β-lactam
combinations. In many bacteria, AmpC enzymes are inducible and can be over-expressed by
mutation thus extending resistance to broad-spectrum cephalosporins i.e. cefotaxime, ceftazidime,
and ceftriaxone [10]. In addition, AmpC can be encoded by plasmids causing its dissemination in
bacteria poorly expressing the chromosomal AmpC gene, such as Escherichia coli, Klebsiella pneumoniae,
and Proteus mirabilis, leading to the development of resistant bacteria overexpressing BLs belonging to
class A and C [13]. In addition, in AmpC producers, the resistance is often co-mediated by mutations
leading to the hyperproduction of AmpC β-lactamase, reduced influx by outer membrane porin loss
and/or enhanced efflux by efflux pump activation.
At present, carbapenems are consider the first-choice drug for the treatment of infection caused by
bacteria expressing multiple BLs and carbapenemases. Unfortunately, the rate of bacteria resistance to
carbapenems is rising. In Enterobacteriaceae producing carbapenemases (CPE), “second line” highly
toxic drugs (i.e., polymyxins, tigecycline, aminoglycosides, and fosfomycin) are often needed [14].
However bacterial strains resistant even to the second-line antibiotic treatment are growing fast
and represent a pressing and challenging issue in anti-infective therapy. New alternatives are
urgently needed.
Among the de novo strategies directed to the inactivation of BLs, the design of covalent BLIs has
represented a successful strategy to counteract resistance in pathogenic bacteria [15]. In this scenario,
boronic acids (BAs) deserve a leading role and their potentiality in the design of pan-spectrum BLI has
been widely demonstrated: Vaborbactam, a cyclic boronic acid active against all SBLs classes, has been
recently approved in therapy [16,17] while others cyclic derivatives are now under investigation as
broad spectrum, cross-classes, BLs inhibitors [18] (Figure 1).
Over the years, we have disclosed several BAs derivatives as well as other non β-lactam
like moieties, active against SBLs and as broad-spectrum cross-classes BLI [19–22]. In some cases,
they have shown interesting biological activity vs. clinical strains and, in light of their chemical
novelty, designed molecules were able to escape pre-existing mechanism of resistance [23]. In a
recent study, we reported the rational optimization of phenylboronic acid derivatives acting as novel,
non-β-lactam-like, micromolar inhibitors of KPC-2 (Figure 1) [24]. The new derivatives restored
susceptibility to meropenem in clinical strains overexpressing KPC-2 while cell-viability assays showed
no cytotoxicity [24]. Considering these promising in vitro and in vivo results and with the intent to
develop broad-spectrum SBLs compounds, in the present work we extended the study to the emergent
carbapenemase GES-5 and to cephalosporinase AmpC. To determine the binding orientation of the most
interesting inhibitors vs GES-5 and AmpC, molecular modeling analysis and X-ray crystallographic
studies were undertaken. The obtained chemical and biological information highlighted the structural
determinant guiding molecular recognition in SBLs and hence targetable in inhibitor design.
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Figure 1. Chemical structures of Vaborbactam [16,17], a representative bicyclic boronate [18], acyclic 
boronic acid derivative BA1 [21,22] and phenylboronic acid 1 [24]. 
2. Results 
2.1. Phenyl Boronic Acid Derivatives as Cross-classes SBLs Inhibitors 
Our small library of derivatives of phenylboronic acid 1 (Figure 1), decorated in ortho or meta 
positions with an acrylic (2–3) or propionic chains (4–5), where assessed against class A (KPC-2 and 
GES-5) and class C (AmpC) SBLs. Ki values were obtained from IC50 as per competitive inhibition 
(Cheng–Prusoff equation) [25], following the inhibition patterns for this series of molecules (Table 1). 
Table 1. Inhibitory profile of phenylboronic acids against Serine β-Lactamases of Class A and C. 
Code Structure KPC-2 
[1] 
Ki μM 
GES-5 [2] 
Ki μM 
AmpC [3] 
Ki μM 
2 
 
2.43 0.11 41.7 
3 
 
31.2 24.6 1.45 
4 
 
1.13 1.83 76.1 
5 
 
53.0 69.4 5.3 
[1] Estimated from IC50 by Cheng–Prusoff equation for competitive inhibition [25]. Reporter substrate 
was nitrocefin (40 μM, Km 36 μM) [24]. [2] Estimated from IC50 by Cheng–Prusoff equation. Reporter 
substrate was nitrocefin (200 μM, Km 208 μM). [3] Estimated from IC50 by Cheng–Prusoff equation. 
Reporter substrate was nitrocefin (200 μM, Km 200 μM). All experiments were performed in triplicate. 
Experimental error never exceeded 5%. 
Analyzing the inhibition profile along the series, all compounds share a broad SBLs inhibitory 
profile with Ki in the micromolar range. Compounds 2–5 highlight the importance of the substitution 
position for the carboxylate moiety in modulating affinity and potency vs class A, here represented 
by KPC-2 and GES-5, and vs class C cephalosporinases, here represented by AmpC. Interestingly, 
results vs class A show ortho derivatives 2 and 4 showing higher potency vs KPC-2 and GES-5 
compared to AmpC, against which the ortho substitution is detrimental for affinity (up to 50-fold 
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2. Results
2.1. Phenyl Boronic Acid Derivatives as Cross-classes SBLs Inhibitors
Our small library of derivatives of phenylboronic acid 1 (Figure 1), decorated in ortho or meta
positions with an acrylic (2–3) or propionic chains (4–5), where assessed against class A (KPC-2 and
GES-5) and class C (AmpC) SBLs. Ki values were obtained from IC50 as per competitive inhibition
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Analyzing the inhibition profile along the series, all compounds share a broad SBLs inhibitory
profile with Ki in the micromolar range. Compounds 2–5 highlight the importance of the su s itution
position for the carboxylate moiety in modulating affinity and potency vs class A, here represented by
KPC-2 and GES-5, and vs class C cephalosporinases, here repres ted by AmpC. Interestingly, r sults
vs class A show ortho erivatives 2 and 4 showi g hig er potency vs KPC-2 and GES-5 compared to
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AmpC, against which the ortho substitution is detrimental for affinity (up to 50-fold drop in potency).
On the contrary meta derivatives 3 and 5 resulted more active against class C with respect to class
A, against which the meta substituent affects negatively the binding affinity (over 600-fold drop in
potency against GES-5 and up to 47-fold against KPC-2) (Table 1).
The binding orientation of compounds 2 and 4 interacting in KPC-2 and GES-5 binding site were
analyzed by X-ray crystallography and molecular modeling, respectively. The results highlighted the
ability for these molecules to interact with the carboxylate-binding pocket in the active site by Arg220,
Ser130, Thr237 and Thr235 in KPC-2 and by Arg244, Ser130, Thr237 and Thr235 in GES-5. For AmpC,
compound 3 was selected for X-ray crystallography studies elucidating the binding potency of meta
derivatives in class C.
2.2. Prediction of the Binding Mode of Compound 2 in GES-5 by Docking Calculation
The sub-micromolar binding affinity of [2-(2-carboxyvinyl)-phenyl]boronic acid (2) against GES-5
(Ki = 0.11 µM) was investigated via covalent docking simulations. The recently disclosed X-ray
structure of GES-5 in complex with a benzothiophene-2-boronic acid derivative (BA1, PDB ID: 6Q35,
Figure 1) [21] was used as the reference protein for docking. Compound 2 was covalent-docked into
GES-5 active site by using the CovDock utility implemented in the Schrodinger suite [26]. The catalytic
hydroxyl group of Ser70 was defined as the reactive site forming a covalent bond by nucleophilic
addition to the boronic acid of the inhibitor 2. The resulting predicted binding mode of 2 in complex
with GES-5 is illustrated in Figure 2.
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the inhibitor deeply in the binding site. Indeed, the boron atom of the boronate moiety is covalently 
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Fig re 2. Docking pose of compound 2 (in green) as predicted in GES-5 active site (P B ID: 6Q35,
teal cartoon). Key catalytic residues are reported in deep teal sticks. H-bond are shown as yellow
dashed line and the salt bridg in th magenta ash d line. Heteroatoms are color-coded (oxygen in
red, nitrogen in blue, boron i pink).
f co pound 2 represents the driving force for the covalent binding to the enzyme, sinki g the
inhibitor deeply in the binding site. Indeed, th boron atom of the boronate moie y is covalently bonded
to the hydroxyl group of the catalytic Ser70, assuming a tetrahedral sp3 hybridization. In additio ,
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the two hydroxyls groups of boronic acid establish a network of H-bonds with the surrounding amino
acids of the catalytic pocket. In particular, one of the two boronic acid hydroxyls interacts with the
carboxylate side chain of Glu166, whereas the second one hydrogen bonds to the backbone CO group
of Thr237 and with the backbone NH group of the catalytic Ser70. According to the hybridization
and geometry assumed by the boronic acid, the inhibitor adopts a de-acylation transition-state analog
conformation [24]. Indeed, one boron oxygen is located in the oxyanion hole, whereas the other
displaces the de-acylation water normally positioned between Glu166 and Ser170.
Comparable to the binding pose of BA1, the phenyl ring of compound 2 is located perpendicularly
to the surface of the catalytic binding pocket, pointing toward the solvent-exposed entrance of the
cleft. However, the smaller aromatic moiety of compound 2 is not able to establish hydrophobic
interactions with the aminoacidic residues of the cleft, as observed for the larger benzo[b]thiophene
ring of compound BA1 (Figure 3) [21].
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Finally, compound 2 orients the ortho carboxyvinyl lateral chain toward the C3(4’) carboxylate
binding pocket, highly conserved in all SBLs, similarly to the binding mode adopted by compound 2 in
complex with KPC-2. The carboxylate group is involved in a pattern of hydrogen bonds with the side
chain hydroxyls of Ser130, Thr235 and Thr237. Interestingly, in GES-5, the carboxylate group seems to
be involved in a strong salt bridge with the positively charged guanidine side chain of Arg244 located
at an average distance of 2.45 Å. In contrast, in KPC-2 in which Arg244 is not conserved, the above
described specific interaction could be picked up by Arg220, oriented in the proximity of the lateral
chain of 2. However, Arg220 in KPC-2 appears oriented in a more distant position respect to that
adopted by Arg244 in GES-5, and an ordered water molecule mediates a specific H-bond interaction
with the carboxylic group of compound 2 (Figure 4). The lack of the salt bridge in KPC-2 justifies the
23-fold higher activity of 2 against GES-5 (Ki of 0.108 µM) with respect to KPC-2 (Ki of 2.43 µM).
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GES-5 protein (PDB ID: 6Q35, teal cartoon), with the X-ray structure of 2 (indigo sticks) in complex
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using the color code adopted for the respective proteins. The corresponding amino acidic numeration
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Comparing the predicted GES-5: compound 2 complex with the X-ray structure of GES-5:BA1
(Figure 3) [21] and the X-ray structure of KPC-2: Compound 2 (PDB ID: 5LL7, Figure 4) [24], close
analogies between binding modes emerged. The binding mode adopted by compound 2 in GES-5
active site closely resembles that of BA1, with the boronic moiety and the aromatic part of the ligand
engaged in similar interactions [21]. Moreover, compound 2 maintains a binding mode similar to
that determined in the previously released X-ray KPC-2: 2: in particular, the later carboxylated chain
is engaged in an extended network of specific interactions, involving Arg244, Thr237, and 235 and
Ser130 [24].
2.3. AmpC-Compound 3 Binary Complex
The structure of the AmpC:3 complex was solved at 1.78 Å resolution, providing a detailed
picture of compound 3 binding orientation in AmpC active site (statistics data are reported in Table S1).
The asymmetric unit contains one protein molecule, 131 water molecules, one molecule of 3 and one
phosphate ion. The electron density for residues Gly1, Glu2, Lys370, and Arg371 was not observed
and was not included in the model. The final model was refined to a Rwork = 17.7% and a Rfree = 20.0%.
Clear electron density in the difference maps was observed in the active site allowing proper fitting of
the inhibitor molecule and determination of any rearrangements in the pocket upon binding.
Inhibitor 3 is covalently bound through the boron atom to the side chain oxygen atom (Oγ) of
Ser64 (Figure 5A,B and Figure S1), adopting a tetrahedral geometry as already reported for other
similar complexes [27,28]. The catalytic and conserved residues in AmpC β-lactamase catalytic domain
undergo minimal rearrangements upon binding (Figure 6).
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Neighboring boronate oxygen atom O14 makes hydrogen bonds with the backbone NH of catalytic
Ser64 and with the backbone NH of Ser319. The boronic acid oxygen atom O13 forms strong hydrogen
bonds with the −OH group of the side chain Tyr150 and with a water molecule W567, commonly highly
conserved in AmpC binary complexes with aryl boronic acid inhibitors [27]. The meta carboxyvinyl
lateral chain of the ligand molecule is placed near Tyr221 and is stabilized by the pi···H−C interaction.
The carboxylate group of the meta carboxyvinyl lateral chain is orientated toward the amide group
of Asn321 and the methyl group of Val213. In class C SBLs, the carboxylate group does not interact
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in the typical carboxylate site of antibiotics as in class A SBLs, but, on the contrary, is oriented in the
opposite direction, towards Asn152, Gln120, and Leu119, where usually the R1 chain of antibiotics
binds [27]. The carboxylate group of the inhibitor 3 is stabilized through the hydrogen bonding of
the oxygen atoms O01 and O03 and water molecules W561 and W502, respectively. Moreover, these
water molecules make a continuous network of hydrogen bonds with the backbone NH of Asn321 and
methyl group of Val213 (Figure S1, for hydrogen bond distances refer to Table S2).
The orientation of the aromatic moiety in the ligand molecule is toward the Asn152, Lys67 and
Leu119 and these residues form C=O···pi, N−H···pi, and O···H−C interactions, respectively, with the
phenyl ring. Moreover, the aromatic moiety is surrounded by residues Gln120 and Asn152 defining
the opening of the binding site.
The PaAmpC:3 monomer superimposes well with the monomer of the native PaAmpC (PDB
ID: 4GZB [30]). The major structural change involves the region near the phenyl ring of compound
3 and comprises a conformational shift of the side chain residues Gln120 and Asn152 (Figure 6).
These residues are important in the substrate selectivity in class C BLs and play an important role
in kinetics of the substrate hydrolysis. Comparing to the structure of native PaAmpC, in the crystal
structure of PaAmpC: 3 the side chain of Gln120 is rotated by 50 degrees and the side chain of the
Asn152 accommodates a flipped orientation and show a shift of 36 degrees. Interestingly, in the crystal
structure of PaAmpC bound to the inhibitor avibactam (PDB ID: 4HEF [30]) these residues superpose
well with the native PaAmpC structure while the largest change is found in the orientation of the
Tyr150 sidechain where avibactam binding causes planar rotation by 50 degrees of the Tyr150 ring [30].
This finding suggests that, depending on the size and bulkiness of the inhibitors, the proximal residues
are prone to arrange to better allocate encumbering structures.
Comparing the complex PaAmpC:3 with that of compound 2 bound to the KPC-2 protein [24],
significant differences in the binding orientation emerged. In KPC-2 the ligand molecule orients
its ortho carboxyvinyl lateral chain towards the carboxylate binding pocket forming a network of
hydrogen bonds with the Thr237, Thr235, Ser130 sidechains and a highly conserved water molecule
(Figure 2). In contrast, in the PaAmpC:3 complex the inhibitor points its meta carboxyvinyl group
towards the opposite direction, extensively interacting with the aqueous solvent (Figure 5B and
Figure S1).
As the matter of fact, in AmpC the lateral carboxylated side chain of 3 does not reach the oxyanion
hole, as for compounds 2 and 4 in class A, being oriented in the opposite direction, thus losing the
possibility to contact key active site residues. No strong specific interactions resulted for the lateral
carboxylated chains, as well as no unfavorable clashes with the protein. This accounts for the similar
binding potency of compounds 3 (Ki 1.45 µM) and 5 (Ki 5.3 µM) with respect to the lead phenylboronic
acid 1 (Ki 4.85 µM) [24].
2.4. Biological Evaluation Against Clinical Strains
To investigate the ability of our phenylboronic acid derivatives 2-5 to reach the periplasmic space,
where SBLs are secreted and concentrated in Gram negative bacteria, and synergically protect β-lactam
antibiotics hydrolysis by BLs, drug interactions model via the fractional inhibitory concentration index
(FICI) was determined against clinical strains overexpressing BLs targets of our studies (Table 2).
FICI of meropenem (MEM) or ceftazidime (CAZ) plus inhibitors against clinical isolates of Klebsiella
pneumoniae expressing KPC-2 and Pseudomonas aeruginosa overexpressing AmpC were employed.
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Table 2. In vitro interaction between antibiotics and boronic compounds determined by fractional
inhibitory concentration index (FICI).
Checkerboard Microdilution Assays and Drug Interaction Model
Strains
MIC [a] Antibiotic FICI [b] Antibiotic + inhibitor
MEM CAZ 2 3 4 5
Klebsiella 99D8 128 - 0.0156 2 0.1250 2
Klebsiella 53A8 128 - 0.0117 2 0.1875 2
Klebsiella 53A9 128 - 0.0175 1.5 0.2500 1.5
P aeruginosa 12 - 32 2 0.5 2 0.3750
P aeruginosa 148 - 128 1 0.375 1.5 0.0936
[a] Minimal Inhibitory Concentration (µg/mL). [b] Synergy is defined when the FICI is ≤0.5, antagonism when the
FICI is >4, and indifference when the FICI is >0.5 and ≤4.
Results from drug–drug interactions assay are consistent with those obtained from the in vitro
studies (Table 1) and the preference for the class of enzymes is maintained in biological tests (Table 2).
Indeed, our phenylboronic acids act synergistically on the base of their preference for class A or class C
enzymes. As far as potency is concerned, compounds 2 and 4 exert a clear synergistic activity towards
Klebsiella pneumoniae strains in combination with MEM, with FICI values well below the cut-off value
of 0.5. Instead, in Pseudomonas aeruginosa compounds 3 and 5, although synergism can be defined
in combination with CAZ, their FICI values are around the cut-off value, with the exception of the
combination CAZ: 5 against P. aeruginosa strain 148.
3. Discussion and Conclusions
A small set of phenylboronic acids were identified as low micromolar inhibitors of SBLs belonging
to class A (KPC-2 and GES-5) and C (AmpC). In biological tests conducted against clinical strains,
BAs derivatives were able to synergically protect meropenem from BLs hydrolysis.
As already observed for KPC-2 inhibition, the derivatization of the phenylboronic acid 1 with the
introduction in ortho position of a carboxylated chain strongly improved affinity vs KCP-2 (2 and 4)
while being detrimental against AmpC. Interestingly, analyzing the activity of the meta derivatives
3 and 5, we noticed a drop in affinity against class A confirming the importance of the carboxylate
moiety orientation to pick specific interactions in KPC-2 and GES-5 binding pockets. The improved
affinity for 2 and 4 against KPC-2 and GES-5 lies in specific interactions in the β-lactam carboxylate
binding pocket [31].
Compounds 3 and 5 do not experience improvement in affinity compared to lead phenylboronic
acid 1, thus reflecting the lack of strong additional specific interactions for meta derivatives in
AmpC binding site [31]. The carboxylated chain in these compounds, despite the possibility to be
accommodated in the catalytic site, cannot reach key recognition binding sites like compounds 2 and
4 in KPC-2 and GES-5, thus resulting in a minimal improvement in activity against class C. On the
contrary, the consistent drop in affinity of the ortho derivatives 2 and 4 against AmpC is probably
related to non-favorable interaction in the active site. As a matter of fact, compounds 2 and 4, though
micromolar inhibitors, due to their ortho derivatization, cannot properly fit in the active site of PaAmpC.
The steric hindrance caused by the orientation of Ser319 and Thr320 in the PaAmpC catalytic pocket
probably disallows a proficuous accommodation of the ortho derivatives.
Interactions targetable in the design of potent phenyl BAs as SBL inhibitors can be derived by
comparing the structure of AmpC in complex with ceftazidime, a class of β-lactam antibiotics, and
PaAmpc:3 structure. In the structure of EcAmpC bound to ceftazidime (PDB ID:1IEL [32]) the carbonyl
oxygen atom O9 of the opened lactam ring establishes the same N-H···O interactions with the main
chain nitrogen atoms of catalytic Ser64 and Ala318 (corresponding to Ser319 in PaAmpc:3) as the
oxygen O14 atom in the PaAmpc: 3 structure. Moreover, the R1 side chain of ceftazidime is stabilized
through the hydrogen bonding of the carbonyl oxygen of the R1 amide group (O12) and Asn152
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and with the pi···pi interaction of the thiazole ring and Tyr221 and adopts the same orientation of the
carboxyvinyl lateral chain of compound 3. The mentioned residues are also important in positioning 3
in the binding pocket of PaAmpC where C=O···pi (between Asn152 and phenyl ring of 3) and pi···H−C
(Tyr221 and the carboxyvinyl chain of 3) interactions are involved in the stabilization of the complex
structure. With respect to compound 3, the R1 side chain of the ceftazidime molecule carries a flexible
carboxylate moiety oriented toward the bulk solvent (Figure S2). In both analyzed structures, the
deacetylating water molecule is present—in the EcAmpC: ceftazidime structure the nitrogen atom N5
of the opened lactam ring is hydrogen-bonded with the water molecule (W402) while in the PaAmpc:
3 structure the same interaction is found between the boronic acid oxygen atom O13 and the water
molecule W567.
Against KPC-2, instead, the ortho derivatives 2 and 4 resulted very active since the acrylic acid
side-chain orients toward the highly conserved carboxylate binding site formed by Thr235, Gly236,
Thr237, and Ser130 similarly to the structure of KPC-2 bound to the β-lactam cefotaxime (PDB
ID:5UJ3 [33]). The existence of the interaction between Trp105 and the phenyl ring of the compound 2
in KPC-2:2 and between Trp105 and the six-membered dihydrothiazine group in KPC-2: cefotaxime
is a consequence of a higher degree of freedom of the Trp105 side chain, prone to adopt the proper
conformation depending on the substrate arrangement (Figure S3).
Similarly to KPC-2, GES-5 is strongly inhibited by the ortho derivatives 2 and 4. The docked
structure of compound 2 in GES-5 active site showed a similar conserved orientation of the carboxylated
side chain as in the structure of the KPC-2:2 complex and like the carboxylate group of the β-lactam
antibiotic in the structure of GES-5 bound to imipenem (PDB ID:pymol [34]) (Figure S4). The C3
carboxylate part of the imipenem molecule is trapped in the carboxylate site and shows a typical
pattern of hydrogen bond interactions mediated through the side chains of residues Ser130, Thr235,
Thr237, Arg244, and a highly conserved water molecule. The key interactions for housing the oxyanion
hole are found for both GES-5: ligand structures (main-chain N atoms of Ser70 and Thr237 with the
ester carbonyl in GES-5: imipenem and backbone CO group of Thr232 and backbone NH group of
the catalytic Ser64 with one of the boronic acid hydroxyls in GES-5:2) (Figure S4). The hydroxyethyl
moiety of imipenem, complementary to the other boronic acid hydroxyl in GES-5:2, interacts with
the Glu166 side chain (corresponds to Glu161 in GES-5:2) and additionally with the side chain of
Asn132. Interestingly, in the docked GES-5:2 structure Glu166 hydrogen bonds to Ser70 which is a rare
case in the class A BLs. Smith et al. (2012) [34] disclosed the importance of this H-bond between the
Glu166 and Ser70 side chains in the GES-5: imipenem complex, suggesting it could play a pivotal role
for the carbapenemase activity. Finally, the existence of the salt bridge between the Arg244 and the
carboxylate group in the GES-5: imipenem structure, as in the docked GES-5:2 structure, contributes to
the higher affinity of the compound 2 against GES-5 than against KPC-2, highlighting the importance
of this particular interaction in the specific inhibitor design targeting class A SBLs.
Antimicrobial assays undertaken against five clinical strains overexpressing the BLs targets of our
study highlighted the ability for our derivatives to synergize β-lactam antibiotics such as CAZ and last
resort meropenem.
Our small boronic acid derivatives have clear potential as cross-class SBLs inhibitors and the
available structures of KPC-2 in complex with compounds 2 and 4, and that of 3 in complex with
AmpC represent a valuable point for future hit-to-lead optimization efforts. Our results highlight
the importance of contacting critical subsite in the catalytic pocket thus opening new perspectives in
the drug design of improved phenylboronic acid broad spectrum SBL inhibitors targeting key and
common spots of SBLs binding site.
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4. Materials and Methods
4.1. Chemistry
Compounds 2–5 (Table 1) were prepared as previously reported [24].
4.2. Proteins Production and Purification
Expression and purification of recombinant KPC-2 and GES-5 have been performed as already
reported [21,24]. For recombinant AmpC from Pseudomonas aeruginosa, the optimized full-length
synthetic gene was purchased (GeneArt service under Life Technologie) and subcloned into pRham
vector to have it in the full-length version. Protein was expressed according to standard protocol:
P. aeruginosa AmpC-β-lactamase was obtained from a culture of E. coli BL21(DE3), carrying the
plasmid vector pRham-AmpC. 1L of LB-medium with kanamycin 50 µg/mL, at 37 ◦C, 150 RPM
for 24 hrs. Expression was induced by 0.2% w/v Rhamnose. After 5–6 hours the cell broth was
centrifuged at 4500 RPM, 4 ◦C, for 20 min. The sample was loaded on a column packed with 25 mL of
Affigel-10 (Biorad) functionalized with 3 MAPB (3-methylaminophenylboronic acid). The column was
previously equilibrated with the loading buffer. The protein was eluted (flow rate, 1 mL/min) with
5 column-volumes of elution-buffer (0.5 M boric acid, 0.5 M NaCl, pH 7.0). β-lactamase activity was
checked in each elution fraction using 200 µM CENTA [35]. Active fractions were pooled, concentrated
by ultrafiltration using a Millipore Ultra-15 (Ultracel-10K; Millipore) and checked by SDS-Page. The
protein pool final concentration (1 mg/mL) was assessed using Bradford and UV-Vis assays. Purified
AmpC β-lactamase was stored at −80 ◦C [36].
4.3. In Vitro Enzyme Inhibition Assays Against KPC-2, GES-5, and AmpC
The half-maximal inhibitory concentration (IC50) of phenylboronic acid derivatives was determined
as follows. Reactions were monitored using a Jasco V-730 spectrophotometer at 485 nm wavelength.
Boronic acids were dissolved in dimethyl sulfoxide (DMSO) to a concentration of 10 mM and stored
at −20◦C. Each compound was tested at concentrations ranging from 1 µM to 200 µM for inhibitory
activity vs full-length KPC-2 enzyme, GES-5 and AmpC in 50 mM of PB + 50 mM KCl at pH 7.4 at
25◦C with 0.01% v/v Triton X-100, to avoid compound aggregation and promiscuous inhibition [37]
in presence of nitrocefin as reported substrate. For tests against KPC-2, reporter substrate nitrocefin
was used at 40 µM, (Km 36 µM) while for tests against GES-5 and AmpC reporter substrate nitrocefin
was used at 200 µM (Km 208 µM and Km 200 respectively). All the experiments were performed in
triplicate. Experimental error never exceeded 5%. The reaction was typically initiated by adding
the enzyme to the reaction buffer last. The IC50 values were determined by measuring the rate of
hydrolysis of a reporter substrate in the presence of five different inhibitor concentrations at λ 482 nm.
The binding affinity ki was estimated, for each compound in the library, from the determined IC50 by
Cheng–Prusoff equation as per competitive inhibition (Table 1) [25].
4.4. Molecular Modeling
4.4.1. Proteins and Ligands Preparations
The crystal structure of GES-5, covalent bounded to benzothiophene-2-boronic acid inhibitor (PDB
ID: 6Q35) was used as a reference protein for docking calculation [21]. The structure was prepared
for calculation by using the Protein Preparation Wizard utilities implemented in Maestro 11.1 of the
Schrodinger suite 2017-1 [38,39]. Epik was used to generate the protonation and tautomeric states of
the residues at pH 7.0 ± 2.0. Water molecules, ions and co-crystallized organic solvent molecules (i.e.,
DMSO, glycerol ethyne glycol) were removed. The hydrogens position and H-bonds were minimized
with the OPLS_2005 force field. The minimized protein was prepared for covalent docking. The
B-O bond between co-crystallized ligand and Ser70 was removed; the hydrogen on the hydroxyl
group of the reactive Ser70 was added back and the co-crystalized ligand removed. The chemical
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structure of compound 2 was drawn using ChemBio3D 14.0 and prepared using the LigPrep module
of Schrödinger suite with the OPLS_2005 force field [40,41]. The prepared protein and the prepared
ligand were merged into one entry in preparation for docking.
4.4.2. Docking Calculation
Covalent docking calculations were performed on the prepared protein structures by using the
CovDock utility implemented in Maestro 11.1 [26]. Covalent Docking in Maestro was performed
by a combination of Glide and Prime programs [26]. Glide was used to dock the small molecule
and Prime was used to run local sampling once the bond has formed between the protein and the
ligand. The hydroxyl group of Ser70 was defined as the reactive site to form a covalent bond to the
boronic acid of the designed inhibitor, as preset by CovDock (Reaction type: boronic acid addition).
The pose prediction protocol was used. No position constraints were applied. Default parameters
were employed for the refinement of docking poses. A maximum of 10 poses per ligand were kept and
subjected to post docking minimization. Docking results were ranked according to their Prime energy
and Glide score. Structural visualization and representation were performed with PyMOL [29].
4.5. Co-Crystallization and Structure Determination
Crystallization of Pseudomonas aeruginosa AmpC in complex with compound 3 ([3-(2-
carboxyvinyl)phenyl] boronic acid]) (PaAmpC:3) was carried out by the hanging drop vapor diffusion
method. Protein sample was concentrated by ultrafiltration to 4 mg/mL in 20 mM NaH2PO4 pH 7.5, 30
mM NaCl and equilibrated over 1.8 M potassium phosphate buffer pH 8.7. The drop was prepared by
mixing the protein and precipitant solutions containing the inhibitor compound (1mM AA647, 2%
DMSO, 1.8 M potassium phosphate buffer pH 8.7) in equal volumes. Crystals appeared after 5 days of
equilibration at 294 K. For data collection, crystals were left to equilibrate in a cryoprotectant solution
containing 20% sucrose, 1.8 M potassium phosphate pH 8.7 and were flash cooled in liquid nitrogen.
Data collection was performed at the ESRF BEAMLINE ID23-1 (Grenoble, France) and PaAmpC:3
crystals gave diffraction data to 1.78 Å resolution. The measured data were processed by XDS [42] and
then solved by molecular replacement with Phenix [43] using the structure of native PaAmpC as the
search model (PDB ID: 4GZB [30]). The resulting model was alternately refined with Refmac5 [44]
implemented in CCP4i and then checked and manually adjusted with Coot [45]. Manual rebuilding
and placement of water molecules was performed with the program Coot as well. The inhibitor
molecule was built and optimized with Elbow [46], manually fitted in the difference maps by using
Coot molecular graphics tools and further refined using Refmac5. LigPlot was used to analyze and
visualize protein-ligand interactions [47] and MolProbity [48] was used for the refinement quality
evaluation. The PaAmpC:3 structure is deposited in PDB as 6S1S (PDB ID).
4.6. Drug Interaction Models Via Checkerboard Microdilution Assay
The in vitro interactions between the antibiotics (meropenem or ceftazidime) used for the
double-disk assay and the boronic acid compounds were investigated by a two-dimensional
checkerboard microdilution assay in microtiter plates, as already described [24]. To assess the
nature of the in vitro interactions between the compounds and antibiotics against selected clinical
strains, the data obtained from the checkerboard assay were used to calculate the fractional inhibitory
concentration index (FICI) [24]. Briefly, exponential cultures of the bacterial strains in Mueller Hinton
broth were inoculated in the wells of microtiter plates containing different concentrations of the cited
antibiotics, with and without phenylboronic acids, and incubated at 37 ◦C for 18 hours. The growth in
each well was quantified spectrophotometrically at 595 nm by a microplate reader TECAN Infinite
(Tecan Trading AG, Switzerland). The minimal inhibitory concentration (MIC) for each drug and
combination of drugs was defined as the concentration of drug that reduced growth by 80% compared
to that of organisms grown in the absence of drug. The fractional inhibitory concentration index (FICI)
Antibiotics 2019, 8, 171 13 of 15
is the mathematical expression of the effect of the combination of antibacterial agents expressed in
Equation (1):
ΣFIC = FICA + FICB =
MICAB
MICA
+
MICBA
MICB
(1)
in which MICA and MICB are the MICs of drugs A and B acting alone, and MICAB and MICBA are the
MICs of drugs A and B in combination. Synergy is defined when the FICI is ≤0.5, antagonism when
the FICI is > 4, and indifference when the FICI is >0.5 and ≤4.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/8/4/171/s1, free
of charge. Table S1: Statistics of data collection, processing and refinement, Table S2: Hydrogen bonds between
ligand molecule 3, PaAmpC residues and water molecules, Figure S1: Key interactions PAAmpC:3, Figure S2.
Overlay of the EcAmpC: ceftazidime and PaAmpC: 3 active sites, Figure S3. Overlay of the KPC-2: cefotaxime
and KPC-2:2 active sites, Figure S4. Overlay of GES-5: imipenem and GES-5:2 active sites.
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